Introduction
Thoracic aortic aneurysm and dissection (TAAD) afflict both sexes, young and old alike, and can be lethal due to rupture. These conditions are attributed to cellular and extracellular matrix (ECM) abnormalities of the medial layer of the aortic wall (1). This layer contains numerous alternating concentric elastic lamellae and smooth muscle cells (SMCs) that are embedded within ECM constituents, including collagens, fibrillins, and glycosaminoglycans. Although SMC death is frequent in end-stage pathology (2), it may not necessarily initiate disease. Indeed, we found that the number of SMCs increases in clinical specimens of sporadic TAAD, particularly in small lesions (3) . Although these descriptive observations cannot infer disease causality, we hypothesized that SMC proliferation could either be an adaptive response to increased hemodynamically induced stress within a dilated aorta or exacerbate disease progression depending on cell phenotype. Unless new, phenotypically similar SMCs replace dying cells precisely, additional progeny will require accommodation within the concentric elastic lamellae that do not increase in number. If daughter cells align side-to-side, they may disrupt homeostatic interactions of SMCs with the ECM; if instead they align end-to-end, this will compel a circumferential growth of the media that could contribute to dilatation. These simple considerations challenge the premise that SMC proliferation represents a therapeutic strategy for TAAD (4, 5) . Importantly, the question of phenotype of the proliferating cells is central to disease outcome and demands further investigation.
Elucidation of genetic etiologies for TAAD has reinforced a possible pathological role for SMC proliferation associated with an impairment of the contractile phenotype. For example, mutations of ACTA2, which encodes smooth muscle α-actin (SMA), result in TAAD characterized by focal areas of proliferating SMCs in the aortic media and marked medial hyperplasia in small arteries (6) . Similarly, mutations of MYH11, which encodes smooth muscle myosin heavy chain (SMMHC), lead to TAAD associated with focal losses but also focal hyperplasia of medial SMCs (7) . Further support for a concept of detrimental hyperplasia is the rare occurrence of ruptured aortic aneurysms in young patients with tuberous sclerosis (8, 9) . This multisystem genetic
Smooth muscle cell (SMC) proliferation has been thought to limit the progression of thoracic aortic aneurysm and dissection (TAAD) because loss of medial cells associates with advanced disease. We investigated effects of SMC proliferation in the aortic media by conditional disruption of Tsc1, which hyperactivates mTOR complex 1. Consequent SMC hyperplasia led to progressive medial degeneration and TAAD. In addition to diminished contractile and synthetic functions, fate-mapped SMCs displayed increased proteolysis, endocytosis, phagocytosis, and lysosomal clearance of extracellular matrix and apoptotic cells. SMCs acquired a limited repertoire of macrophage markers and functions via biogenesis of degradative organelles through an mTOR/β-catenin/MITF-dependent pathway, but were distinguishable from conventional macrophages by an absence of hematopoietic lineage markers and certain immune effectors even in the context of hyperlipidemia. Similar mTOR activation and induction of a degradative SMC phenotype in a model of mild TAAD due to Fbn1 mutation greatly worsened disease with near-uniform lethality. The finding of increased lysosomal markers in medial SMCs from clinical TAAD specimens with hyperplasia and matrix degradation further supports the concept that proliferation of degradative SMCs within the media causes aortic disease, thus identifying mTOR-dependent phenotypic modulation as a therapeutic target for combating TAAD.
Chronic mTOR activation induces a degradative smooth muscle cell phenotype expresses membrane-targeted tdTomato, a variant red fluorescent protein (RFP), except where excised by Cre to express membrane-targeted GFP (20) . DNA recombination was induced by tamoxifen treatment of 1.5-week-old Tsc1 fl/fl Myh11-CreER T2 mT/mG mice, while control litters were treated with corn oil vehicle. Efficiency and specificity of recombination were confirmed by disruption of Tsc1, loss of its product hamartin, selective expression of GFP instead of RFP by medial cells, and increased mTOR activity in all regions of the aorta (Supplemental Figure 1 ; supplemental material available online with this article; https://doi.org/10.1172/ JCI131048DS1). In certain experiments, control SMCs expressing GFP were obtained from tamoxifen-treated Myh11-CreER T2 mT/mG mice lacking Tsc1 fl/fl . Animals with conditional disruption of Tsc1 were serially sacrificed and their aortas compared with controls. At 12 weeks of age, 20% of thoracic aortas exhibited aneurysms (greater than 1.5-fold fusiform dilatation or any saccular dilatation) and dissections (blood within the vessel wall) ( Figure 1, A and B ). Although the unloaded ascending aortas were dilated with increased mass, they were not elongated ( Figure 1C ). There were no differences in descending thoracic aorta dimensions or cardiac and body mass (Supplemental Figure 2A) , and vessels other than the thoracic aorta had a normal appearance (not shown). Disease manifestations in the thoracic aorta progressively worsened. The incidence of TAAD increased to 33% at 24 weeks and 55% by 36 weeks, at which time ascending segments were also elongated and descending segments dilated ( Figure 1D and Supplemental Figure 2 , B and C). Mean blood pressure and pulse pressure, but not heart rate, were significantly lower, thus excluding hypertension as a cause of the aortic pathology ( Figure 1E ). Antemortem ultrasound examination verified larger-diameter ascending aortas with diminished distension during the cardiac cycle (Figure 1, F and G and Supplemental Figure 2D ). Excised ascending segments demonstrated blunted responses to vasoconstrictors that worsened considerably with duration of Tsc1 disruption, translating to impaired reduction of pressure-induced circumferential stress on the vessel wall from decreased vasoconstriction ( Figure 1H and Supplemental Figure 2 , E and F). Biomechanical analysis also revealed progressive losses of elastically stored energy, a key functional metric of the aorta, and late increases in circumferential material stiffness (Supplemental Figure 2 , G and H and Supplemental Tables 1 and 2) , which often associates with aneurysms (21) . This progressive vascular dysfunction ex vivo suggested intrinsic vessel wall defects.
SMC proliferation and elastin fragmentation characterize the aortic pathology. Vessel sections were analyzed by histomorphometry to determine cellular and ECM changes. Ascending aortas with conditional Tsc1 disruption exhibited luminal dilatation and medial expansion at 12 weeks ( Figure 2 , A and B); a larger circumference and thicker wall contributed to the increased medial area (Supplemental Figure 3A ). The media also had more cells per cross section, without any change in cell density (Figure 2 , C and D). SMC proliferation was confirmed by increased BrdU uptake at 5 and 12 weeks, whereas SMC apoptosis, as assessed by a TUNEL assay, was initially low and not increased until 24 weeks (Figure 2 , E-H and Supplemental Figure 3B ). Strikingly, there was increased elastin fragmentation in all ascending segments and partial elastin loss throughout the thoracic aorta at 12 weeks ( Figure 2 , I and J), disease is caused by mutations in TSC1 or TSC2, which encode the proteins hamartin and tuberin, respectively, that together form the tuberous sclerosis complex that acts as a tumor growth suppressor by inhibiting mTOR, a key kinase regulating cellular growth and differentiation (10) . Among diverse manifestations, individuals with tuberous sclerosis present with mesenchymal tumors consisting of proliferating SMCs and characterized by mTOR hyperactivation. A second-hit somatic mutation to the unaffected allele is postulated for tuberous sclerosis lesions, an event that may occur with insufficient frequency in vascular SMCs to induce overt aortic disease. Nevertheless, histological analysis of a rare thoracoabdominal aneurysm in a child with a TSC2 mutation revealed SMC hyperplasia in the inner media with diminished SMA expression and extensive fragmentation of elastic fibers (11) . In accompanying studies on Tsc2 +/− mice, cultured SMCs also showed increased proliferation and decreased contractile protein expression with an exaggerated neointimal formation following wire injury. Although the hemizygous phenotype is mild, these findings support the concept that mTOR drives SMC dedifferentiation, consistent with in vitro studies that the mTOR inhibitor rapamycin promotes SMC differentiation toward a contractile phenotype (12) .
Vascular SMCs demonstrate marked phenotypic modulation, originally observed to range from contractile in quiescent mature arteries to proliferative and synthetic in disease or injury. Dedifferentiation can thus involve loss of contractile molecules and increased synthesis of ECM (13) . Phenotypic changes in SMCs are not constrained along this contractile-to-synthetic spectrum, however. Chondrogenic and osteogenic phenotypes lead to accumulated glycosaminoglycans and calcification, while trans differentiation into other cell types is also possible. Macrophage-like cells derived from SMCs accrue in atherosclerotic lesions and contribute to neointima expansion; they are not detected in the media, however (14) . Previous studies of medial SMC changes in TAAD have described loss of contractile proteins and acquisition of synthetic properties, as described for intimal SMCs in atherosclerotic disease (15) (16) (17) .
In this study, we investigated whether SMC proliferation promotes or prevents TAAD and how mTOR modulates SMC phenotype. Toward this end, we used postnatal SMC-specific disruption of Tsc1 in mice as well as treatment with the mTOR inhibitor rapamycin. The data reveal that an mTOR-dependent proliferation of SMCs rich in lysosomes and expressing a subset of macrophage markers causes TAAD. Moreover, hyperactivation of mTOR exacerbates disease in a prior mouse model of mild TAAD. There is, therefore, strong motivation to target the mTOR-dependent degradative SMC phenotype when seeking to treat diverse thoracic aortopathies.
Results

Postnatal disruption of Tsc1 in SMCs causes progressive aortic disease.
To investigate effects of increased mTOR activity and SMC proliferation in the aortic wall, we bred mice with 3 transgenes: (a) the mTORC1 inhibitor Tsc1, with exons 17 and 18 flanked by loxP sites (18) Figure 3 , H and I). Electron microscopy at 24 weeks confirmed elastic fiber attenuation, while SMCs displayed disordered cytoplasmic filaments and more perinuclear organelles that extended peripherally ( Figure 2K ). In summary, cellular and ECM abnormalities contributed to the observed medial expansion and degeneration. Loss of Tsc1 causes mTORC1 hyperactivation, whereas mTOR inhibition rescues the aortic phenotype. Perturbations in mTOR signaling were assessed by Western blotting of thoracic aorta lysates after consistent with the aforementioned decreased elastic energy storage. Elastin breaks were greater in the subset of vessels with TAAD and vessel wall architecture was more disordered at 36 weeks when most thoracic aortas were aneurysmal or dissected (Supplemental Figure 3C ). Elastin degradation was minimal in arteries other than the thoracic aorta, and markedly less in the ascending aorta if induction of Cre activity was delayed to 12 weeks of age; degradation was not a result of tamoxifen administration or GFP expression, as it did not occur in mutants lacking Myh11-CreER T2 or Tsc1 fl/fl (Supplemental Figure 3 , D-G). Collagen did not accumu- Figure 4A ). Akt phosphorylation diminished by 12 weeks, likely via feedback inhibition by S6K as previously reported (22) , and expression of contractile molecules also diminished ( Figure 3B ), consistent with the functional finding of impaired contractility. Altered mTOR signaling did not depend on the hemodynamic environment because similar findings persisted in vitro, there was no downregulation of mTORC1 signaling overnight fasting of animals. Disruption of Tsc1 increased activation of the mTOR complex 1 (mTORC1) at 3 weeks of age, as indicated by greater phosphorylation of its effectors, S6K, S6, and 4EBP1 ( Figure 3A ). Phosphorylation of the mTORC2 substrate Akt at serine 473 and expression of contractile proteins, such as SMMHC, SMA, and SM22, were not significantly altered at this early time, although there was less activation of a contractile regulator, myosin or upregulation of contractile proteins in response to serum withdrawal in cultured, Tsc1-deficient, GFP + SMCs, while repressed mTORC2 signaling was more apparent in the absence of growth factors (Supplemental Figure 4B ). Administration of the mTOR inhibitor rapamycin to Tsc1-deficient mice ablated mTORC1 activ-ity without changing mTORC2 activity and increased contractile protein expression in the thoracic aorta ( Figure 3C ). Rapamycin therapy from 2 to 12 weeks prevented TAAD formation (Figure 3 , D-I), albeit with reduced somatic growth (Supplemental Figure  5 , A-D). Treatment with rapamycin from 12 to 24 weeks, i.e., after disease initiation, also prevented TAAD progression (Supplemental Figure 5 , E-G). Phenotypic rescue by the highly specific drug rapamycin (23) excludes mTOR-independent effects of the tuberous sclerosis complex as causes of the aortic disease (24) . Medial degeneration associates with impaired elastogenesis and greater elastolysis. We investigated if elastic fiber fragmentation results from abnormal production and/or breakdown. Because medial elastin synthesis decreases after P21 (25), we quantified the abundance of ECM transcripts in the thoracic aorta at 3 weeks ( Figure 4A ). mRNA expression for Eln (encoding elastin), Fbn1 (encoding fibrillin-1), and Col3a1 (encoding type III collagen) was decreased, while that for Myh11, Acta2, and Myl9 (encoding MLC2) was unchanged, consistent with contractile protein expression at this early time. In vitro culture of aortic SMCs from 3-weekold mice also revealed decreased elastin and microfibrillar protein synthesis ( Figure 4 , B and C and Supplemental Figure 6 , A and B). Ascending aortas from 12-week-old mice were also more susceptible to elastic fiber digestion by extrinsic enzyme (Figure 4 , D Figure 4F ). We assessed elastase activity of mural cells using a protease-activatable fluorescent imaging agent administered in vivo followed by flow cytometric analysis of isolated aortic cells. 7, C-F). Flow cytometry verified the limited repertoire of macrophage markers by the GFP + SMCs, albeit with low expression of CD68 (Supplemental Figure 7 , G and H). Further multiparameter studies revealed heterogeneous SMC populations with differing LAMP2 and GAL3 expression, thus excluding a single macrophage-like cell type ( Figure 5G ). LAMP2 single expressers were smaller, GAL3 single expressers were larger, and double expressers were more granular with greater production of MMP2 ( Figure  5H ). Rapamycin treatment from 2 to 24 weeks of age decreased, to below basal levels, SMC size, granularity, polyploidy, and the expression of LAMP2 and GAL3, suggesting that physiological stimuli also contribute to this phenotype; rapamycin treatment for 1 week was less effective (Supplemental Figure 8, A and B) . Moreover, chronic mTOR inhibition eliminated the expansion of dedifferentiated SMA lo SMCs characterized by LAMP2 and GAL3 expression (Supplemental Figure 8 , C-E). These data indicate phenotypic modulation of medial SMCs by dysregulated mTOR signaling characterized by a limited range of macrophage markers.
Phenotypically altered SMCs exhibit markers of degradative organelles. To identify additional molecules expressed by modulated SMCs with incomplete macrophage markers, we performed whole-transcriptome profiling at 24 weeks (data deposited in NCBI's Gene Expression Omnibus: GSE135177 and GSE135240). Both bulk RNA sequencing (RNA-seq) of whole thoracic aortas (Supplemental Table 3 ) and single-cell RNA-seq of isolated GFP + SMCs (Supplemental Table 4 ) delineated experimental conditions with similar changes in selected genes of interest ( Figure  6 , A-C and Supplemental Figure 9 ). Expression of multiple contractile molecules was downregulated, as was that of many ECM molecules typically produced in the aortic wall. Notwithstanding induction of several innate immunity markers (e.g., Lamp2, Lgals3 encoding GAL3, Tlr2, and Ly96), many pan-leukocyte and myeloid lineage markers (e.g., Ptprc encoding CD45, Cd56, Itgam encoding CD11b, Lyz2, Ly6c2, Csf1r, Ccr2, Cx3cr1, Fcgr2b, and Fcgr3) were absent in GFP + SMCs, although they were expressed by a subset of contaminating GFP − cells (Supplemental Figure 10 ). Besides Lamp2, there was also upregulation of other lysosomal genes (e.g., Lamp1, Cd63, Ctsd, Ctsl, Atpv0b, Atp6ap1, Hexa, and Npc2) as well as markers of other organelles that contribute to intracellular digestion, such as autophagosomes (e.g., Gabarap, Gabarapl1, Map1lc3b, and Sqstm1), endosomes (e.g., Rab7), and phagosomes (e.g., Axl and Gas6). Induction of cytokine, chemokine, adhesion molecule, and protease genes (e.g., Spp1 encoding osteopontin, Cx3cl1, Vcam1, and Mmp2) suggested SMC activation. Identification of larger numbers of discriminating genes by deep learning that clustered similar cells showed similar phenotypic changes in SMCs of diverse origin, that is, with or without neural crestassociated transcription factors (26) , and independent of cell damage, namely, with or without induction of mitochondrial RNA (27) (Supplemental Figure 11 ). Gene ontology analysis identified "proton-transporting V-type ATPase complex" (which acidifies the lysosomal lumen) in bulk RNA-seq data and "membrane-bounded organelles" in single-cell RNA-seq data among enriched terms characterizing the differences across experimental conditions (Supplemental Tables 5 and 6 ). Additionally, "proteolysis" and "catabolic process" were highly ranked in SMC clusters characterized by increased lysosome-related molecules (Supplemental increased expression of MMP2 within the media, particularly in ascending aortas at 24 weeks (Figure 4 , I and J). Increased MMP2 expression by isolated GFP + SMCs but not RFP + cells was verified by flow cytometry (Figure 4 , K and L) and zymography confirmed increased MMP2 activity in cultured cells (Supplemental Figure 6 , C and D). Collectively, these observations demonstrate sequential changes of aberrant elastin synthesis at 3 weeks followed by greater susceptibility to proteolysis by 12 weeks plus increased induction of proteolytic enzymes between 12 and 24 weeks, all consistent with the progressive degeneration of the medial layer of the thoracic aorta found biomechanically and histologically following Tsc1 disruption.
Medial SMCs acquire a subset of macrophage markers. Given the progressive loss of contractile and synthetic functions, both defining features of SMCs, we considered possible differentiation into other cell types in the absence of cell loss. Lineage tracing by GFP expression unambiguously identified SMCs that remained within the medial layer, but they had transformed from a spindle to epithelioid morphology with increased cell size and enlarged nuclei ( Figure 5A ). Flow cytometric analysis of enzymatically dispersed cells confirmed the increased size as well as increased granularity and polyploidy of GFP + SMCs ( Figure 5, B and C). These medial cells did not exhibit adipogenic, chondrogenic, or osteogenic phenotypes (Supplemental Figure 7A ), but they did express a few macrophage antigens common to intimal SMCs in atherosclerotic plaques (14) , such as lysosomal associated membrane protein-2 (LAMP2, also known as Mac-3), galectin-3 (GAL3, also known as Mac-2), and MOMA-2 (uncharacterized antigen), particularly in the ascending aorta, and this expression increased from 12 to 24 weeks ( Figure 5 β-catenin) in addition to multiple lysosomeand autophagosome-associated genes. Of the microphthalmia family of transcription factors known to regulate lysosomal biogenesis, Mitf and Tfe3 correlated with lysosome-related genes and Ctnnb1, whereas Tfeb correlated with smooth muscle contractile markers. Bulk RNA-seq analysis of aortic tissue revealed increased Ctnnb1 and Mitf, unchanged Tfe3, and decreased Tfeb expression after Tsc1 disruption ( Figure  7A ). Correspondingly, β-catenin and MITF, but not TFE3 or TFEB protein expression, was increased in vivo by Western blot (Figure 7 , B and C). Expression of β-catenin and MITF was localized to medial SMCs by immunofluorescence analysis (Figure  7 , D and E). Such differences in expression were also noted in cultured SMCs, and MITF translocated to the nucleus following Wnt activation in vitro (Supplemental Figure 13 ). Levels of β-catenin, MITF, and lysosomal membrane proteins in cultured SMCs depended on mTOR activity (Figure 7F ). Furthermore, knockdown of Ctnnb1 and Mitf decreased expression of lysosomal membrane proteins (Figure 7 , G-I). These results indicate a coordinated regulation of lysosomal biogenesis in degradative SMCs by mTOR, β-catenin, and MITF.
Medial SMCs gain degradative functions. To determine if the altered phenotype enriched in markers of degradative organelles had functional consequences, we further characterized properties of isolated SMCs in vitro. Increased numbers of acidic vesicles extended peripherally from their normal perinuclear location as documented by an acidotropic tracker dye ( Figure 8A ), consistent Figure 12 ). Thus, transcript expression supports the concept of an SMC phenotype characterized by markers of degradative organelles that is neither part of the contractile-to-synthetic spectrum nor a result of transdifferentiation of SMCs into conventional macrophages.
An mTOR/β-catenin/MITF pathway in SMCs regulates lysosomal biogenesis. We searched for genes that may be linked to lysosomal biogenesis in SMCs by coexpression analysis of the single-cell RNA-seq data (Supplemental Table 7 ). Lamp2 showed high correlation to the Wnt signaling effector Ctnnb1 (encoding confocal microscopy were verified by flow cytometry (Figure 8C ).
Receptor-mediated endocytosis of fibronectin by cultured SMCs is well established (28) , and this assay of ECM uptake revealed both greater accumulation and degradation of labeled fibronectin ( Figure 8D ). In contrast, long-term treatment with rapamycin in with similar in situ findings of more numerous and widespread organelles by electron microscopy. Increased lysosomal function was determined with conjugated bovine serum albumin in which self-quenched fluorescence is detectable only after hydrolysis ( Figure 8B ). Differences in lysosomal number and function by firmed by transcriptional profiling and flow cytometry that fatemapped SMCs from atheromatous aortas of tamoxifen-treated ApoE −/− Myh11-CreER T2 mT/mG control mice did not express macrophage markers except for lysosome-associated molecules (Supplemental Figures 17 and 18 ). These outcomes support pathogenic effects of mTOR activation in SMCs on aortic disease beyond models of tuberous sclerosis. SMCs with degradative phenotype occur in human TAAD. Finally, to determine if these many experimental findings are relevant to human disease, we analyzed both aneurysmal and nondilated ascending aorta specimens from 24 patients. The subject groups differed for sex, age, bicuspid aortic valve, and dyslipidemia (Supplemental Table 8 ). Among other cell types, CD45 + leukocytes expressed LAMP2 (Mac-3) within the inflamed intima, while SMMHC + SMCs expressed LAMP2 within the bland media (Figure 10, A and B) . Medial SMCs of aneurysmal aortas expressed greater LAMP2 and less SMMHC than nondilated controls (Figure 10C ). An inverse correlation of LAMP2 to SMMHC expression further suggested increased lysosomes in dedifferentiated SMCs. Additionally, aneurysms displayed characteristic elastin fragmentation and LAMP2 expression correlated with loss of elastin (Figure 10 , D and E). As previously reported (3), small thoracic aortic aneurysms had more medial cells than referent nondilated vessels and LAMP2 expression correlated with the number of medial cells (Figure 10 , F and G and Supplemental Table 8 ). LAMP2 expression also correlated to medial thinning and ascending aorta dilatation ( Figure 10H ). Furthermore, mTOR signaling was increased in TAAD, and SMCs with detectable mTOR activity had increased expression of LAMP2 (Supplemental Figure 19) . With a caveat of potentially confounding clinical differences among subject cohorts, medial SMCs with a degradative phenotype manifest in human TAAD, thus supporting a pathological role.
Discussion
Our findings elucidate a role of dramatic SMC modulation in TAAD. SMCs with mTOR-dependent proteolytic and phagocytic activity drive TAAD formation. Moreover, these degradative SMCs do not fit within the canonical spectrum of contractileto-synthetic phenotypic modulation typical of many arterial diseases and their upregulation of lysosomal markers does not imply transdifferentiation into conventional macrophages. Rather, these proliferative SMCs exhibit a unique subset of degradative properties that compromise aortic medial properties and function, thereby rendering the wall vulnerable to dilatation and dissection. Hence, promoting SMC proliferation without maintaining appropriate function will not prevent TAAD. Indeed, this could worsen medial degeneration and exacerbate TAAD.
We used a model of conditional Tsc1 disruption to test a hypothesis focused on altered SMC function, not to recreate a rare aortic disease of children with heterozygous germline mutations affecting the tuberous sclerosis complex (8, 9, 11) . Importantly, this model revealed that mTORC1 hyperactivation leads to increased proliferation of medial SMCs and progressive TAAD. Medial degeneration and luminal dilatation initially affect the ascending aorta, and then extend distally with age. Differences in mechanical stresses or in embryological origins of SMCs may dictate segmental vulnerability (31, 32) . Diminished elastic fiber vivo decreased SMC uptake and breakdown of fibronectin (Supplemental Figure 14A ). SMCs also displayed increased phagocytosis of labeled, insoluble elastin fragments in coculture ( Figure  8E ). Although most cells accumulated small (<1 μm) elastin particles within perinuclear vesicles, a minority characterized by high rhodamine fluorescence also contained relatively large (>1 μm) elastin inclusions ( Figure 8F) . Because mural hemorrhage and medial cell death may occur with TAAD progression, we also tested for phagocytosis of labeled, heat-damaged cells and found increased efferocytosis of erythrocytes, mononuclear cells, and damaged SMCs by viable SMCs (Figure 8G and Supplemental Figure 14, B and C) . The vacuoles containing elastin particles or damaged erythrocytes were lined by lysosomal membrane proteins, identifying the structures as phagolysosomes (Supplemental Figure 14 , D and E). We defined a functional role for Axl and Gas6, both of which were increased in RNA-seq analyses, using neutralizing Axl antibodies and soluble Axl-Fc chimeric proteins ( Figure  8H ). Interestingly, phagocytosis of erythrocytes may occur in vivo in the absence of overt mural bleeding, as we documented occasional TER-119 + cells within or contiguous to medial GFP + SMCs of nondissected thoracic aortas ( Figure 8I ). The finding of infrequent, large cytoplasmic vacuoles containing amorphous material by electron microscopic examination of tissue sections suggested in vivo SMC phagocytosis (Supplemental Figure 14F) . These observations establish that Tsc1-deficient SMCs are more efficient at uptake and degradation of ECM and cellular debris.
mTOR-transformed SMCs are deleterious in diverse models of aortic disease. Because degradative SMCs could promote either reparative or pathological processes (e.g., by removing ECM debris or breaking down intact ECM), we investigated consequences of mTOR hyperactivation in an experimental model of mild TAAD attributable to a clinically relevant mutation of Fbn1. We previously reported activation of mTOR signaling in the thoracic aortas of Fbn1 C1039G/+ mice (29) and found increased LAMP2 + and GAL3 + SMCs late in the disease course (Supplemental Figure 15 ). In contrast with controls, Fbn1 C1039G/+ Tsc1 fl/fl Myh11-CreER T2 mT/mG mice induced with tamoxifen at 1.5 weeks presented markedly enlarged ascending aortas by ultrasound and gross examination at 12 weeks of age ( Figure 9, A and B ), well before that in Fbn1 C1039G/+ mice (29) . Strikingly, almost all compound mutants died from aortic rupture between 12 and 24 weeks (Figure 9 , C and D). Greater disease severity was associated with mTOR activation and an increased frequency of LAMP2/GAL3 + SMCs (Figure 9 , E and F). We also investigated effects of a degradative SMC phenotype on aortic atherosclerosis by crossing Tsc1 mutants with ApoE -/mice, because hyperlipidemia is reported to drive transdifferentiation of SMCs into macrophages (30) . To avoid plaque disruption by aortic dissection, we delayed the administration of tamoxifen to 7 weeks of age, or 1 week prior to the initiation of a high-fat, high-cholesterol diet, that resulted in a low incidence of TAAD (17%) at 24 weeks, with dissected vessels excluded from analysis. Conditional disruption of Tsc1 increased lipid accumulation within the aorta that localized to intimal cells as well as medial SMCs adjacent to and remote from intimal plaques (Supplemental Figure 16, A and B) . Medial and, particularly, intimal GFP + SMCs expressed the lysosomal marker LAMP2 but not the pan-leukocyte marker CD45 on confocal microscopy (Supplemental Figure 16 , C and D). We conjci.org Volume 130 Number 3 March 2020 described in clinical TAAD specimens based on increased expression of the nonstructural glycoprotein osteopontin, normally a minor component of the media (15) (16) (17) . Similarly, TAADs can exhibit increased type V and XI but decreased type I and III collagen production, again in contrast to the classical synthetic SMC phenotype (43) . Our mouse model of conditional mTOR hyperactivation documents decreased abundance of transcripts for many ECM molecules that contribute to aortic wall structure, including Col1a1, Col1a2, Col3a1, Col4a1, Col5a1, and Col6a1 but increased expression of other transcripts encoding matrix proteins usually detected at low levels in the media, such as Spp1 (encoding osteopontin) and Col8a1. The latter ECM molecules are preferentially expressed by arterial fibroblasts (44) ; thus, the activated SMCs could be designated as fibroblast-like. Because these populations of SMCs also express increased lysosome-related molecules they may be also interpreted as macrophage-like. Although SMCs with increased phagocytic properties may be classified as macrophages ("big eaters") based on a functional definition, they differ from myeloid cells. Our preference is to avoid designating pathological SMC functions as like that of other cells because there may be overlap with multiple cell types and this need not imply transdifferentiation into other mature somatic lineages. We favor relating the altered cellular phenotype to dominant structural or functional changes at the tissue level -hence degradative SMCs. Our observations build on the multiple functions described for SMCs in arterial health and disease, including perturbations of endocytosis, phagocytosis, and autophagy (45, 46) . Importantly, different phenotypes of SMCs can coexist within the media, hence revealing considerable cellular heterogeneity both spatially and temporally that may overlap with functions of other mural cell types. We found that medial degeneration after Tsc1 disruption associates with increased proteolytic activity and macromolecule clearance by a spectrum of degradative SMCs. We also found MMP2 as a major extracellular protease and multiple lysosomal cathepsins as intracellular proteases; phagocytosis, endocytosis, and lysosomal hydrolysis by SMCs all increased. An association of increased MMP activity with TAAD is well documented, but few reports link lysosomal cathepsins to arterial aneurysms and those involve vessels other than the thoracic aorta and may relate to infiltrating leukocytes (47, 48) . Increased proteolysis is not necessarily pathological if part of adaptive vessel wall remodeling and increased clearance of extracellular debris may be reparative and promote recycling of macromolecules. Notably, myometrial SMCs rich in lysosomes and containing degraded matrix components and phagocytosed erythrocytes characterize the rapidly involuting uterus postpartum that returns to a preinvolutional state within weeks, indicating both a physiological role for degradative myocytes as well as reversible phenotype switching (49) . Nevertheless, these same processes can also lead to medial degeneration of the aorta when dominant. Degradative SMCs with both decreased contractile and synthetic functions is not part of the contractileto-synthetic spectrum associated with occlusive arterial disease and argues for a unique phenotype contributing to TAAD.
Phagocytosis, a characteristic macrophage function, is accomplished to a lesser degree by diverse nonhematopoietic cell types, including SMCs (50). Additionally, SMCs acquire several macro-integrity and associated loss of elastic energy storage initiates aortic remodeling in our model and is multifactorial with distinct temporal onsets: (a) aberrant elastic fiber synthesis, (b) enhanced susceptibility to proteolysis, (c) diminished SMC contractility reducing stress shielding of the ECM, (d) greater protease production, and (e) degradative organelle biogenesis with increased macromolecule clearance. In addition to the manifestation of spontaneous disease, despite the lower blood pressure, these abnormalities exacerbate aortopathy resulting from other causes, such as fibrillin-1 mutation.
SMC proliferation is recognized as contributing to occlusive but not aneurysmal arterial disease. Conspicuous acellular areas of the aneurysmal media have long been recognized in end-stage disease and it is intuitive to relate cell death to medial thinning and mural rupture (2) . Yet, SMC loss also occurs in nondilated aortas (33) and foci of SMC hyperplasia are found in TAAD (6, 7, 34) . Few studies have counted aortic SMCs. Consistent with our previous report (3), the present data confirm that medial area can increase in thin-walled aneurysmal thoracic aortas and SMC density can remain unchanged, hence revealing increases in the number of SMCs per cross section and thus hyperplasia unless due to cell migration. Similar findings of preserved SMC density in TAAD have been reported independently (15) , while others report 58%-150% increases (34, 35) or 23%-36% decreases (36, 37) , with variations across studies perhaps highlighting focal differences. Moreover, SMC death does not necessarily cause TAAD. Selective SMC apoptosis in mice leads to aortic wall thinning without outward remodeling (38) ; aortic allografts in nonimmunosuppressed patients function as valved conduits without aneurysmal enlargement even with inevitable SMC death (39) . These observations suggest that viable cellular participants are required to remodel extant ECM and allow aortic dilatation. Although early induction of medial cell hyperplasia in our model temporally coincides with certain dysfunctional properties (e.g., decreased elastin synthesis at 3 weeks of age), the incremental increase in degradative markers from 12 to 24 weeks implies chronic indicators of and stimuli for phenotypic modulation. Additionally, the limited efficacy of short-term versus long-term rapamycin treatment in reversing the phenotype implies structural alterations that are not readily reversible. Pathological hyperplasia of dysfunctional cells is consistent with the paradigm that SMCs play a central role in TAAD pathogenesis, either preventing disease via homeostatic functions or accelerating disease by inappropriate responses.
During aortic development, immature SMCs produce abundant ECM prior to the upregulation of contractile proteins (25) . Conversely, mature SMCs express abundant contractile markers and synthesize relatively low levels of ECM as required for vessel wall maintenance and adaptation to altered mechanical loads. Changes in arterial SMC phenotype characterized by increased ECM production and decreased contractile proteins occurs in atherosclerotic plaques as well as during in vitro culture (40, 41) and such contractile-to-synthetic modulation is often referred to as dedifferentiation. Although increased production of type I and III collagen is a distinguishing feature of synthetic SMCs (42) , such synthesis need not include all ECM proteins produced during development. Indeed, a synthetic phenotype of SMCs is often jci.org Volume 130 Number 3
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TFEB and TFE3 as additional regulators of lysosomal biogenesis in SMCs under different conditions and multiple regulatory pathways for a degradative phenotype may exist. Effective prevention of TAAD by rapamycin after Tsc1 disruption demonstrates that mechanisms for medial degeneration in this model depend on mTOR. Rapamycin also successfully prevents aortopathy in other experimental models with diverse mechanisms including diminishing SMC hyperplasia, maintaining SMC contractility, reducing synthetic and proinflammatory SMC phenotypes, decreasing protease production, and suppressing leukocyte recruitment and activation (29, (65) (66) (67) (68) . Translation to clinical trials should be tempered, however, by known side effects such as impaired wound healing and thus possible adverse effects on adventitial fibrosis and tensile strength (68) . Targeting specific degradative functions may have fewer side-effects. Because lysosomal function is essentially a housekeeping activity in all nucleated cells, it is unlikely that broad antagonism of lysosomal activity will be well tolerated as chronic preventative therapy for TAAD. Selective inhibitors of lysosomal enzymes or proton pumps may be effective and should be explored.
Methods
Mice. C57BL/6J (stock no. 000664), Tsc1 fl/fl (stock no. 005680), mT/mG (stock no. 007676), and ApoE -/-(stock no. 002052) mice were purchased from the Jackson Laboratory. Myh11-CreER T2 were a gift from Stefan Offermanns (available from Jackson Laboratory as stock no. 019079) and Fbn1 C1039G/+ mice were a gift from Harry C. Dietz (available from Jackson Laboratory as stock no. 012885). Mutant strains were bred to the C57BL/6J background for more than 6 generations. Male mice were euthanized at various ages for analysis (the BAC containing Myh11-CreER T2 inserts on the Y chromosome and female mice do not express the construct).
Animal treatment. Cre-Lox recombination was induced by tamoxifen (Sigma-Aldrich) at 200 μg/d p.o. q.d. for 5 days usually starting at 1.5 weeks of age, while controls were treated with vehicle (corn oil) alone. A subgroup of animals received BrdU (Sigma-Aldrich) at 1 mg s.c. q.o.d. from 3 to 5 or 10 to 12 weeks of age. Certain animals were treated with rapamycin (Calbiochem) at 2 mg/kg/d i.p. q.d. or DMSO vehicle alone for variable durations as described, including a final dose 12 hours before euthanasia. Some animals received a highfat (40 kcal% fat), high-cholesterol (1.25% w/w), cholic acid-free diet (Research Diets, D12108) from 8 to 24 weeks of age.
In situ and ex vivo examination. After euthanasia, the body cavities were opened widely and in situ images of the thoracic aorta were obtained using an SZX16 dissecting microscope with a camera attachment (Olympus). The unpressurized width (external diameter) of the mid-ascending aorta and proximal descending aorta was measured in triplicate. The unpressurized length of aorta was measured along its outer curvature from the ventricular-aortic junction to the proximal origin of the brachiocephalic artery for the ascending segment and from the distal origin of the subclavian artery to the diaphragmatic hiatus for the descending segment. The aorta was then excised from heart to diaphragm, imaged ex vivo, and weighed. The heart and body were also weighed, body length was measured from snout to anus, and body width was measured at the level of the diaphragm. Aortic dimensions were measured from digital images using a calibrated software tool, whereas body length and width were directly measured with a ruler. phage markers in response to lipid accumulation (51) . Although phenotypic modulation of SMCs into phagocytic cells has been described by some investigators as transdifferentiation (30, 51) , this process defines conversion of one mature somatic cell type into another. Mac-2, Mac-3, and CD68 were first identified by monoclonal antibodies that distinguish tissue macrophages from precursor monocytes, that is, based on functional maturation and not by hematopoietic lineage (52) (53) (54) . Yet, these antigens are not specific for macrophages; they are expressed at low levels by a variety of nonhematopoietic cells. Subsequent molecular studies identified Mac-2 as GAL3, a multi functional protein selectively recruited to damaged lysosomes, Mac-3 as LAMP2, a major lysosomal membrane protein, and CD68, also known as LAMP4, as homologous to lysosomal membrane proteins with a significant fraction localizing to lysosomes (55) (56) (57) . We find subpopulations of SMCs with chronic mTOR activation expressing LAMP2, GAL3, and, to a lesser extent CD68, but not hematopoietic lineage markers or many markers of specialized immune functions. These findings are consistent with our assays of increased lysosomal activity in activated SMCs but not for transdifferentiation of SMCs into macrophages. We also could distinguish SMCs with increased expression of lysosome-related markers from perivascular myeloid cells in hyperlipidemic control mice without Tsc1 disruption, although we examined all aortic cells and did not select rare intimal populations that may exist below the detection limits of our techniques. An advantage of our models is the use of double-reporter strains that decrease artifacts from SMC-macrophage doublets, phagocytosis of one cell type by another, and autofluorescent extracellular debris. Cells with double-as well as singlereporter constructs may, however, exhibit overlapping fluorescence from transgenic proteins and autofluorescent metabolites or particles. Thus, we excluded double-positive (RFP + /GFP + ) events that were increased in mice fed a high-fat, high-cholesterol diet and constitute a potential source of artifact (58) . It is possible that rare SMC-derived phagocytes containing autofluorescent lipid and a more complete repertoire of macrophage markers reside within this population unsuitable for fluorescence analysis. Distinguishing between phagocytic SMCs and conventional macrophages is important for understanding disease mechanisms, but metaplasia at the tissue level occurs from altered cellular functions regardless of the cell of origin.
Chronic mTOR activation is not expected to result in catabolic cellular processes because physiological mTOR activation from nutrient starvation or growth factor withdrawal leads to phosphorylation and decreased nuclear translocation of TFEB, the master transcriptional regulator of lysosomal biogenesis (59) . Persistent starvation, however, reactivates mTORC1 and restores the lysosomal pool (60) . Additionally, hyperactivation of mTORC1 from Tsc1 or Tsc2 disruption upregulates a subset of lysosomal genes and promotes endocytosis (61) . Although TFEB expression is decreased in mTOR-activated SMCs, the related transcription factor MITF is increased. MITF was previously described to be stabilized by Wnt signaling and to drive endolysosomal biogenesis (62) . Furthermore, β-catenin activity is increased in SMC tumors resulting from mutations in TSC1 or TSC2, although this effect is celltype specific, as β-catenin and MITF are decreased in melanocytes in tuberous sclerosis (63, 64 RT-PCR and quantitative RT-PCR. Crushed tissue was immersed in RLT lysis buffer (Qiagen) and vigorously vortexed. Total RNA was isolated using an RNeasy Mini Kit and DNase Digestion Set (Qiagen) according to the manufacturer's protocol. Reverse transcription reactions were performed using an iScript cDNA Synthesis Kit (Bio-Rad). PCR was performed using cDNA, PCR Greenmix (Sigma-Aldrich), and primers specific for Tsc1 exon17 (forward 5′-AGCAGCATGCACT-CAGGAACAG-3′; reverse 5′-TCTGGCTATGCAGTTGGGTCAC-3′) and Actb (forward 5′-CCAGTTGGTAACAATGCCATGT-3′; reverse 5′-GGCTGTATTCCCCTCCATCG-3′). The solution was separated by 1.5% agarose gel. Quantitative RT-PCR was performed using a Bio-Rad CFX94 by mixing equal amount of cDNAs, TaqMan gene master mix, and primers for Eln (Mm00514670_m1), Fbn1 (Mm00514908_ m1), Col3a1 (Mm00802300_m1), Myh11 (Mm00443013_m1), Acta2 (Mm00725412_s1), Myl9 (Mm00725412_s1), and Hprt (Mm03024075_m1) from TaqMan. RNase-free ddH 2 O was used as negative controls for qPCR instead of cDNA samples. All reactions were in a 12.5 μL volume, in duplicate. PCR amplification consisted of 10 minutes of an initial denaturation step at 95°C followed by 40 cycles of PCR at 95°C for 15 seconds, and 60°C for 1 minute. We confirmed stable expression of several house keeping genes.
Fluorescence microscopy. Mouse aortas were fixed overnight in 4% PFA at 4°C and either embedded in paraffin or cryoprotected in 15% sucrose for 6-8 hours at 4°C and embedded in OCT (Tissue-Tek). Human aorta specimens were immediately embedded in OCT. Tissue blocks were sectioned at 5 μm. For paraffin sections, the slides were dewaxed in xylene and boiled for 30 minutes in citrate buffer (Vector) for antigen retrieval. Alternatively, frozen sections of human aorta were fixed in acetone for 10 minutes at -20°C prior to immunostaining. Paraffin sections were labeled with antibody against BrdU (catalog ab6326, Abcam) after denaturing with 1 M HCl for 15 minutes and TUNEL assay (Sigma-Aldrich) was performed according to the manufacturer's instructions. Frozen sections were labeled with phalloidin (Thermo Fisher Scientific) or an antibody against MMP2 (catalog Ultrasound. Transthoracic B-mode images of the thoracic aorta were obtained in lightly isoflurane anesthetized animals using a Vevo 770 high-frequency ultrasound (VisualSonics). Transverse dimensions of the mid-ascending thoracic aorta were measured in triplicate at end-diastole and end-systole. Aortic distension was calculated as the diameter change during the cardiac cycle.
Blood pressure. The aorta was catheterized via the right carotid artery using a 1.4-F Mikro-Tip pressure catheter (Millar Instruments), and blood pressure was measured in lightly anesthetized mice using a PowerLab system (ADInstruments).
Histomorphometry. Aortas were fixed in 4% paraformaldehyde (PFA) overnight and embedded in paraffin. Serial 5-μm-thick transverse sections were stained in batches by Yale's Research Histology Laboratory with H&E, Verhoeff-Van Gieson, Verhoeff without counterstain, Masson's trichrome, Sirius red, Alcian blue/Von Kossa, and Oil Red O using standard techniques and an automated system. Morphometry was performed using ImageJ software (http://rsbweb. nih.gov/ij/) after outlining the internal and external elastic laminae. Lumen area was calculated within the internal elastic lamina (because it closely approximates the adjacent endothelial perimeter). Medial area and mean thickness were calculated between the internal and external elastic laminae. The number of medial cells was calculated by counting hematoxylin-stained nuclei and expressed either as cell density (per mm 2 ) or as total number of cells (per cross section) and elastin breaks were counted from Verhoeff-Van Gieson-stained transverse sections. Protein was quantified from histological images using ImageJ for monochromatic stains or a custom color segmentation algorithm for polychromatic stains; relative amount was calculated as percentage area of positive staining in vessel wall compartments on tissue sections and integrated density for nuclear and cytoplasmic cellular staining. Similar techniques were used for human specimens, except intima and adventitia thickness was measured and medial cell density was counted in 3 high-power fields in each of the inner, mid, and outer media, averaged, and total cells were extrapolated from the media area calculated from media thickness, adventitia thickness, and external aorta diameter measurements. En face preparations of 4% PFA-fixed murine aortas were stained with Oil Red O for 1 hour, rinsed in 60% isopropanol for 10 seconds, and the extent of Oil Red O staining as percentage aorta surface area was measured using ImageJ.
Transmission electron microscopy. The ascending aortas of 24-week-old mice were fixed (2% PFA and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at pH 7.4) for 1 hour at room temperature, and then stored in the same buffer at 4°C until processing. Specimens were postfixed in 1% OsO 4 in the same buffer at room temperature for 1 hour. After en bloc staining with 2% aqueous uranyl acetate for 1 hour, the tissue was dehydrated in a graded series of ethanol up to 100%, followed by propylene oxide, and then embedded in EMbed 812 resin and the sample blocks were polymerized at 60°C overnight. Thin sections (60 nm) were cut with an EM UC7 ultramicrotome (Leica) and poststained with 2% uranyl acetate and lead citrate. Sample grids were examined in a Tecnai G2 Spirit BioTwin transmission electron microscope (FEI) at 80 kV of accelerating voltage and digital images were recorded with a SIS Morada CCD camera (Olympus) with iTEM imaging software.
Western blotting. Animals were fasted overnight prior to euthanasia for signaling studies, except for tests of rapamycin treatment. The thoracic aorta was rapidly excised by sharp dissection to remove surjci.org Volume 130 Number 3 March 2020 between 2 groups was by Student's t test, more than 2 groups by 1-way ANOVA for 1 independent variable, 2-way ANOVA for 2 independent variables, and repeated-measures ANOVA for assays over time, followed by Tukey's or Sidak's multiple-comparisons tests if the null hypothesis was rejected by ANOVA. Comparison of categorical variables between 2 groups was by Fisher's exact test and of survival distribution between 2 groups by log-rank test. Correlations were examined by the Spearman test and linear regression of the data modeled the relationship between variables. Probability values were 2-tailed and P < 0.05 was considered to indicate statistical significance. Graph construction and statistical analyses were performed with Prism 8.2.0 (GraphPad Software). Study approval. Animal research protocols were approved by the Institutional Animal Care and Use Committee of Yale University. Human subjects research protocols with a waiver for consent were approved by the Institutional Review Boards of Yale University and the New England Organ Bank.
